Navigation Links
New discovery brings customized tuberculosis therapies based on genotype closer to reality
Date:8/1/2011

Bethesda, MDAre you genetically predisposed to tuberculosis? Scientists may now be able to answer this question and doctors may be able to adjust their therapeutic approach based on what they learn. That's because new research presented in the Journal of Leukocyte Biology (http://www.jleukbio.org) suggests that two frequent mutations in an immune system gene called TLR1 are responsible for cellular changes that ultimately make us less likely to resist the disease.

"The study may help to characterize individuals with increased susceptibility to tuberculosis, which might result in faster and more effective recognition and therapy of this disease," said Lothar Rink, Ph.D., a researcher involved in the work from the Institute of Immunology at RWTH Aachen University Hospital in Aachen, Germany. "We hope that our results have implications for understanding the pathogenesis of mycobacterial infections associated with TLR1."

To make this discovery, scientists tested 71 healthy individuals and found that about half lacked the toll like receptor 1 (TLR1) proteins necessary for the immune system to adequately recognize Mycobacterium tuberculosis. Using specific TLR1 agonists, researchers found that cells without TLR1 (TLR-negative) showed a decreased functionality when compared to cells with TLR1 (TLR-positive). Sequencing and genotyping of TLR1-positive and TLR1-negative cells from healthy individuals revealed that lack of TLR1 surface expression accompanied by impaired function was strongly associated with increased susceptibility to tuberculosis. Further studies are needed to confirm that a TLR1-negative genotype accounts for hyporesponsiveness to mycobacterial infections or for tuberculosis vaccination.

"Antibiotics have been helpful in managing tuberculosis in the developed world," said John Wherry, Ph.D., Deputy Editor of the Journal of Leukocyte Biology, "but unfortunately, these treatments are expensive, take a long time and are becoming less effective against drug-resistant strains. Understanding why some people are more likely than others to become infected should help prioritize who should receive drug treatment in the developing world and lead to strategies for universal vaccines or therapeutics."

According to the U.S. Centers for Disease Control and Prevention, tuberculosis one-third of the world's population are infected with TB, with more than 9 million people around the world becoming sick with tuberculosis each year. Nearly 2 million people die from tuberculosis each year worldwide. In the United States, there were 11,545 tuberculosis cases reported in 2009. The bacteria that cause tuberculosis usually attack the lungs, but they can attack any part of the body such as the kidney, spine, and brain. If not treated properly, tuberculosis can be fatal. The disease is spread through the air from one person to another. The bacteria that cause the disease are put into the air when a person with active tuberculosis of the lungs or throat coughs, sneezes, speaks, or sings. People nearby may breathe in these bacteria and become infected.


'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert

Related biology news :

1. Chemical equator discovery will aid pollution mapping
2. Sirtris review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery
3. Groundbreaking discovery may lead to stronger antibiotics
4. Discovery of natural compounds that could slow blood vessel growth
5. Nanoscopic screening process to speed drug discovery
6. FSU researchers discovery leads to $1.5 million grant, potential new treatment of liver fibrosis
7. New $11 million center to speed production of new compounds for drug discovery
8. Discovery of giant roaming deep sea protist provides new perspective on animal evolution
9. New discovery may enhance MRI scans, lead to portable MRI machines
10. Kidney function discovery sheds light on genetic complexity of disease
11. Discovery of new gene associated with diabetes risk suggests link with body clock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2016)... FRANCISCO , June 16, 2016 ... size is expected to reach USD 1.83 ... by Grand View Research, Inc. Technological proliferation and ... banking applications are expected to drive the market ... ) , The development of advanced ...
(Date:6/3/2016)... June 3, 2016 ... Nepal hat ein ... hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und ... der Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche ... im Januar teilgenommen, aber Decatur wurde als ...
(Date:5/24/2016)... care by providing unparalleled technology to leaders of the medical imaging industry.  As such, ... to the range of products distributed by Ampronix. Photo - http://photos.prnewswire.com/prnh/20160524/371420 ... ... ... With ...
Breaking Biology News(10 mins):
(Date:6/22/2016)...  According to Kalorama Information, the dominant trends ... include significant efforts in automation as well as ... affordable sequencers, say the healthcare market research firm, ... sample prep materials.  The healthcare market research company,s ... Next Generation Sequencing (NGS) , highlights major trends ...
(Date:6/22/2016)... DIEGO , June 22, 2016   ViaCyte, ... first pluripotent stem cell-derived islet replacement therapy for the ... presentations at ISSCR 2016 Annual Meeting.  ISSCR 2016, the ... to 25th at Moscone West in San Francisco.  ... of the presentations are as follows:Event: , Focus Session: ...
(Date:6/22/2016)... 22, 2016  Mesa Biotech Inc., a privately-held, ... platform designed specifically for point-of-care (POC) infectious disease ... advisory board (SAB). Approved by the executive leadership ... chartered to advise on the development and commercialization ... by Dr. Steve Young , this world-class ...
(Date:6/21/2016)... , June 22, 2016 Frontier Biotechnologies Inc. ... its novel patch product AB001 met primary endpoint at ... relief against placebo. Conducted at nine clinical centers in ... enrolled 146 patients with chronic low back pain. AB001 ... week-1 (p=0.024), (2) greater reduction than placebo in the ...
Breaking Biology Technology: